Download PDF
Dtsch Med Wochenschr 2021; 146(13/14): 908-910
DOI: 10.1055/a-1449-4995
Dossier

Update 2021: COVID-19 aus Sicht der Intensivmedizin

Update 2021: COVID-19 from the perspective of intensive care
Stephanie-Susanne Stecher
,
Hans Joachim Stemmler
,
Dennis A. Eichenauer
,
Matthias Kochanek
,
Alexander Shimabukuro-Vornhagen
,
Michael von Bergwelt-Baildon
,
Boris Böll
› Further Information
Also available at
    Permissions and Reprints

COVID-19 stellt weiterhin hohe Ansprüche an die Intensivmedizin. Im Verlauf der Pandemie gelang es immer mehr, für viele Herausforderungen Lösungen zu finden. Dennoch bleiben Fragen offen, besonders was die personelle Situation auf den Intensivstationen angeht. Dieser Beitrag stellt eine Aktualisierung insbesondere der Erkenntnisse zu Diagnostik und Therapie der letzten Monate aus Sicht der Intensivmedizin dar.

Abstract

COVID-19 continues to challenge health-care systems and ICUs around the globe more than one year into the pandemic and in spite of all advances in diagnosis and treatment of the disease caused by the novel SARS-CoV-2. Many open questions remain concerning optimal medical therapy, respiratory management and resource allocation, particuly in times of limited available health care personell. In the following short article, we summarized current knowlegde on management of COVID-19 in the ICU.

Schlüsselwörter

Corona - Pandemie - COVID-19 - ARDS - SARS-CoV2

Key words

Corona - pandemia - COVID-19 - ARDS - SARS-CoV2


Publication History

Article published online:
13 July 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA – J. Am. Med. Assoc 2021; 323 (18) 2020-2021
    PubMedGoogle Scholar
  • 2 Kluge S, Janssens U, Welte T. et al. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19. Med Klin Intensivmed Notfmed 2020; 115: 175-177 DOI: 10.1007/s00063-020-00674-3.
    CrossrefPubMedGoogle Scholar
  • 3 Manson JJ, Crooks C, Naja M. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020; 9913 (20) e594-e602
    CrossrefPubMedGoogle Scholar
  • 4 Dargent A, Chatelain E, Kreitmann L. et al Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS. PLoS ONE 2020; 15 (07) e0236312 DOI: 10.1371/journal.pone.0236312.
    CrossrefPubMedGoogle Scholar
  • 5 Karagiannidis C, Mostert C, Hentschker C. et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 2020; 8: 853-862
    CrossrefPubMedGoogle Scholar
  • 6 Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA 2020; 324 (13) 1292-1295 DOI: 10.1001/jama.2020.16747.
    CrossrefPubMedGoogle Scholar
  • 7 The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Authors and Members of the Writing Committee. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis. JAMA – J. Am. Med. Assoc 2020; 324 (13) 1330-1341
    CrossrefPubMedGoogle Scholar
  • 8 Mouncey PR, Rowan KM, Nichol AD. et al. N Engl J Med 2021; 384 (16) 1491-1502
    CrossrefPubMed
  • 9 Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10285): 1637-1645
    CrossrefPubMedGoogle Scholar
  • 10 Barbaro RP, Maclaren G, Boonstra PS. et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396 (10257): 1071-1078
    CrossrefPubMedGoogle Scholar